This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Forward Step By Step With Action Plan 2016 - Continued Revenue Growth - Significant Pipeline Progress

With Janssen, Evotec also announced the licensing of a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. The agreement between Evotec and Janssen triggered an upfront payment of $ 8 m. Upon achievement of certain pre-clinical, clinical, regulatory and commercial goals, Evotec could receive milestone payments of up to $ 300 m per product. In addition, Janssen will pay royalties on future sales of any products that result from this collaboration.

Evotec achieved key milestones within its product development alliance with MedImmune in the field of beta cell regeneration and received two milestone payments totalling € 1 m. EVT770 is currently in pre-clinical development and could enter trials within 24 months.

In addition Evotec signed two co-development agreements with Haplogen and Apeiron. With Haplogen Evotec aims to discover and develop small molecules against viral infectious diseases and with Apeiron the objective of developing immunomodulatory lead compounds for the treatment of cancer.

After the success of Cure Beta with Harvard University, Evotec and Harvard started their second strategic alliance, including Brigham and Women's Hospital and the University of Southern California aimed at discovering and developing new biomarkers and treatments in the field of kidney disease. This programme CureNephron is designed to deliver and exploit novel therapeutic targets as well as biomarkers that allow more accurate diagnosis, monitoring and treatment of chronic and acute kidney disease.

An open innovation alliance was formed with Yale University. Under the agreement, Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need ready for partnering.

Two product development collaborations were terminated during the course of 2012. The EVT401 agreement in animal health and the VR1 collaboration with Pfizer ended, because of strategic portfolio reviews pursued by the respective partners.

5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs